Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review

Gopi B. Shah, Linde De Keyzer, Joy A. Russell, Ashleigh Halderman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: A major component of sputum in cystic fibrosis (CF) patients is polymerized DNA, a byproduct of degraded neutrophils. Dornase alfa (dornase) selectively cleaves extracellular DNA and reduces the viscosity of sputum. It improves mucociliary clearance and pulmonary function. The benefit of dornase on CF-associated sinusitis is less clear. Therefore, the objective of this study was to systematically review the use of dornase on chronic rhinosinusitis (CRS) in CF patients. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed for this systematic review. Ovid Medline, EMBASE, PubMed, and the Cochrane Library were searched. The search terms “dornase alfa,” “deoxyribonucleases,” “rhinosinusitis,” and “cystic fibrosis” were used to find articles published between 1990 and 2016. The articles were reviewed for study design, level of evidence, and clinical outcomes. Results: Sixty-two articles were identified; 6 met the inclusion criteria (104 patients). Improvement measured by sinonasal symptoms, endoscopic and radiographic findings, and pulmonary function was variably reported between the studies. Sinonasal symptoms were shown to improve in all studies with use of intranasal topical dornase. Three placebo-controlled studies showed that topical dornase significantly improved sinonasal symptoms more than saline alone. The impact on pulmonary function and radiographic and endoscopy findings was variable. Conclusion: Topical intranasal dornase appears to improve sinonasal symptoms in CF patients to a greater degree than saline alone. The impact on other outcomes is less clear. Larger studies are needed to fully elucidate the true efficacy of dornase alfa in the treatment of CRS in CF patients.

Original languageEnglish (US)
Pages (from-to)729-736
Number of pages8
JournalInternational Forum of Allergy and Rhinology
Volume8
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Cystic Fibrosis
Sputum
Lung
Therapeutics
Mucociliary Clearance
Deoxyribonucleases
DNA
Sinusitis
PubMed
Viscosity
Endoscopy
Libraries
Meta-Analysis
dornase alfa
Neutrophils
Placebos

Keywords

  • CFTR
  • deoxyribonuclease
  • drug delivery
  • genetics
  • neutrophils
  • sinonasal

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis : a systematic review. / Shah, Gopi B.; De Keyzer, Linde; Russell, Joy A.; Halderman, Ashleigh.

In: International Forum of Allergy and Rhinology, Vol. 8, No. 6, 01.06.2018, p. 729-736.

Research output: Contribution to journalArticle

@article{b1fdf7971e3d45d2b928a34e719621b8,
title = "Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review",
abstract = "Background: A major component of sputum in cystic fibrosis (CF) patients is polymerized DNA, a byproduct of degraded neutrophils. Dornase alfa (dornase) selectively cleaves extracellular DNA and reduces the viscosity of sputum. It improves mucociliary clearance and pulmonary function. The benefit of dornase on CF-associated sinusitis is less clear. Therefore, the objective of this study was to systematically review the use of dornase on chronic rhinosinusitis (CRS) in CF patients. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed for this systematic review. Ovid Medline, EMBASE, PubMed, and the Cochrane Library were searched. The search terms “dornase alfa,” “deoxyribonucleases,” “rhinosinusitis,” and “cystic fibrosis” were used to find articles published between 1990 and 2016. The articles were reviewed for study design, level of evidence, and clinical outcomes. Results: Sixty-two articles were identified; 6 met the inclusion criteria (104 patients). Improvement measured by sinonasal symptoms, endoscopic and radiographic findings, and pulmonary function was variably reported between the studies. Sinonasal symptoms were shown to improve in all studies with use of intranasal topical dornase. Three placebo-controlled studies showed that topical dornase significantly improved sinonasal symptoms more than saline alone. The impact on pulmonary function and radiographic and endoscopy findings was variable. Conclusion: Topical intranasal dornase appears to improve sinonasal symptoms in CF patients to a greater degree than saline alone. The impact on other outcomes is less clear. Larger studies are needed to fully elucidate the true efficacy of dornase alfa in the treatment of CRS in CF patients.",
keywords = "CFTR, deoxyribonuclease, drug delivery, genetics, neutrophils, sinonasal",
author = "Shah, {Gopi B.} and {De Keyzer}, Linde and Russell, {Joy A.} and Ashleigh Halderman",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/alr.22082",
language = "English (US)",
volume = "8",
pages = "729--736",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis

T2 - a systematic review

AU - Shah, Gopi B.

AU - De Keyzer, Linde

AU - Russell, Joy A.

AU - Halderman, Ashleigh

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: A major component of sputum in cystic fibrosis (CF) patients is polymerized DNA, a byproduct of degraded neutrophils. Dornase alfa (dornase) selectively cleaves extracellular DNA and reduces the viscosity of sputum. It improves mucociliary clearance and pulmonary function. The benefit of dornase on CF-associated sinusitis is less clear. Therefore, the objective of this study was to systematically review the use of dornase on chronic rhinosinusitis (CRS) in CF patients. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed for this systematic review. Ovid Medline, EMBASE, PubMed, and the Cochrane Library were searched. The search terms “dornase alfa,” “deoxyribonucleases,” “rhinosinusitis,” and “cystic fibrosis” were used to find articles published between 1990 and 2016. The articles were reviewed for study design, level of evidence, and clinical outcomes. Results: Sixty-two articles were identified; 6 met the inclusion criteria (104 patients). Improvement measured by sinonasal symptoms, endoscopic and radiographic findings, and pulmonary function was variably reported between the studies. Sinonasal symptoms were shown to improve in all studies with use of intranasal topical dornase. Three placebo-controlled studies showed that topical dornase significantly improved sinonasal symptoms more than saline alone. The impact on pulmonary function and radiographic and endoscopy findings was variable. Conclusion: Topical intranasal dornase appears to improve sinonasal symptoms in CF patients to a greater degree than saline alone. The impact on other outcomes is less clear. Larger studies are needed to fully elucidate the true efficacy of dornase alfa in the treatment of CRS in CF patients.

AB - Background: A major component of sputum in cystic fibrosis (CF) patients is polymerized DNA, a byproduct of degraded neutrophils. Dornase alfa (dornase) selectively cleaves extracellular DNA and reduces the viscosity of sputum. It improves mucociliary clearance and pulmonary function. The benefit of dornase on CF-associated sinusitis is less clear. Therefore, the objective of this study was to systematically review the use of dornase on chronic rhinosinusitis (CRS) in CF patients. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement was followed for this systematic review. Ovid Medline, EMBASE, PubMed, and the Cochrane Library were searched. The search terms “dornase alfa,” “deoxyribonucleases,” “rhinosinusitis,” and “cystic fibrosis” were used to find articles published between 1990 and 2016. The articles were reviewed for study design, level of evidence, and clinical outcomes. Results: Sixty-two articles were identified; 6 met the inclusion criteria (104 patients). Improvement measured by sinonasal symptoms, endoscopic and radiographic findings, and pulmonary function was variably reported between the studies. Sinonasal symptoms were shown to improve in all studies with use of intranasal topical dornase. Three placebo-controlled studies showed that topical dornase significantly improved sinonasal symptoms more than saline alone. The impact on pulmonary function and radiographic and endoscopy findings was variable. Conclusion: Topical intranasal dornase appears to improve sinonasal symptoms in CF patients to a greater degree than saline alone. The impact on other outcomes is less clear. Larger studies are needed to fully elucidate the true efficacy of dornase alfa in the treatment of CRS in CF patients.

KW - CFTR

KW - deoxyribonuclease

KW - drug delivery

KW - genetics

KW - neutrophils

KW - sinonasal

UR - http://www.scopus.com/inward/record.url?scp=85040546423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040546423&partnerID=8YFLogxK

U2 - 10.1002/alr.22082

DO - 10.1002/alr.22082

M3 - Article

C2 - 29323796

AN - SCOPUS:85040546423

VL - 8

SP - 729

EP - 736

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

IS - 6

ER -